Study of BIIB091 Formulations in Healthy Participants
An Open-Label, Pharmacokinetic Study to Evaluate the Pharmacokinetics and Relative Bioavailability of BIIB091 Formulations and to Assess the Impact of Food, a Proton Pump Inhibitor and CYP3A4 Inhibitor on BIIB091 Exposure Using the Selected Formulation in Healthy Subjects
Sponsor: Biogen
A PHASE1 clinical study on Healthy Volunteers, this trial is completed. The trial is conducted by Biogen and has accumulated 11 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
May 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Nov 2022 — May 2023 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Apr 2022 — Nov 2022 [monthly]
Recruiting PHASE1
▶ Show 6 earlier versions
-
Dec 2021 — Apr 2022 [monthly]
Recruiting PHASE1
-
Jun 2021 — Dec 2021 [monthly]
Recruiting PHASE1
-
Apr 2021 — Jun 2021 [monthly]
Recruiting PHASE1
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Oct 2020 — Nov 2020 [monthly]
Not Yet Recruiting PHASE1
First recorded
Sep 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Biogen
For direct contact, visit the study record on ClinicalTrials.gov .